Related Experiment Videos
[Sclerosing cholangitis and ulcerative colitis. Regional prevalence]
H H Rasmussen1, J F Fallingborg, P B Mortensen
1Aalborg Sygehus, medicinsk gastroenterologisk afdeling M.
Ugeskrift for Laeger
|January 10, 1994
Summary
This study found primary sclerosing cholangitis (PSC) in 3.6% of ulcerative colitis (UC) patients. PSC prevalence in UC requires further investigation despite no clear link to UC severity.
Area of Science:
- Gastroenterology
- Hepatology
- Epidemiology
Background:
- Ulcerative colitis (UC) is an inflammatory bowel disease.
- Primary sclerosing cholangitis (PSC) is a chronic liver disease often associated with IBD.
- Understanding PSC prevalence in UC patients is crucial for patient management.
Purpose of the Study:
- To determine the prevalence of primary sclerosing cholangitis (PSC) in a regional cohort of ulcerative colitis (UC) patients.
- To investigate potential associations between UC characteristics and PSC development.
Main Methods:
- A 12-year retrospective study of 305 UC patients.
- Screening for elevated serum alkaline phosphatase (> 280 U/l).
- Diagnostic confirmation of PSC using endoscopic retrograde cholangiography (ERC).
Main Results:
- Eleven out of 305 UC patients (3.6%) were diagnosed with PSC.
- Five PSC patients experienced disease progression, including two deaths from cholangiocarcinoma within six years.
- No significant correlation was found between UC extent, duration, or activity and PSC presence.
- Alkaline phosphatases were elevated up to 3.7 times the upper reference level; aminotransferases showed only mild elevation.
Conclusions:
- The prevalence of PSC in this UC cohort is 3.6%.
- PSC can be progressive and associated with significant mortality in UC patients.
- Current UC disease parameters do not reliably predict PSC development.